Add-on immunosuppressive therapy may benefit selected patients with primary biliary cholangitis and autoimmune phenomena.
Mengqi LiSha ChenShuxiang LiTingting LvBuer LiShan ShanMin LiNa ZengQianyi WangYuanyuan KongHong MaXin-Yan ZhaoXiaojuan OuHong YouWeijia DuanJi-Dong JiaPublished in: Therapeutic advances in gastroenterology (2024)
Add-on immunosuppressive therapy may improve the normalization rates of transaminase and IgG levels in all patients with PBC and mildly elevated transaminase and IgG levels and the long-term outcomes in the subgroup of the patients with transaminase ⩾3 × ULN or IgG ⩾1.3 × ULN.